GoodRx Holdings, Inc. (GDRX) reported $197.88 million in income for the quarter ended March 2024, representing a year-over-year enhance of seven.6%. EPS of $0.08 for a similar interval compares to $0.07 a yr in the past.
The reported income compares to the Zacks Consensus Estimate of $196.2 million, representing a shock of +0.86%. The corporate delivered an EPS shock of -11.11%, with the consensus EPS estimate being $0.09.
Whereas traders intently watch year-over-year adjustments in headline numbers — income and earnings — and the way they examine to Wall Road expectations to find out their subsequent plan of action, some key metrics all the time present a greater perception into an organization’s underlying efficiency.
Since these metrics play a vital position in driving the top- and bottom-line numbers, evaluating them with the year-ago numbers and what analysts estimated about them helps traders higher undertaking a inventory’s value efficiency.
Right here is how GoodRx carried out within the simply reported quarter when it comes to the metrics most generally monitored and projected by Wall Road analysts:
- Month-to-month Lively Customers: 7 in comparison with the 7 common estimate based mostly on three analysts.
- Subscribers: 778 versus the two-analyst common estimate of 866.
- Income- Prescription transactions: $145.40 million in comparison with the $145.51 million common estimate based mostly on 5 analysts. The reported quantity represents a change of +7.8% yr over yr.
- Income- Different: $5.38 million versus $4.89 million estimated by 5 analysts on common. In comparison with the year-ago quarter, this quantity represents a +19.4% change.
- Income- Pharma Producer Options: $24.51 million versus $23.21 million estimated by 5 analysts on common. In comparison with the year-ago quarter, this quantity represents a +20.1% change.
- Income- Subscription: $22.60 million versus $22.56 million estimated by 5 analysts on common. In comparison with the year-ago quarter, this quantity represents a -6.2% change.
View all Key Company Metrics for GoodRx here>>>
Shares of GoodRx have returned +8.7% over the previous month versus the Zacks S&P 500 composite’s -0.3% change. The inventory at the moment has a Zacks Rank #3 (Maintain), indicating that it may carry out according to the broader market within the close to time period.
Zacks Names “Single Finest Choose to Double”
From 1000’s of shares, 5 Zacks consultants every have chosen their favourite to skyrocket +100% or extra in months to come back. From these 5, Director of Analysis Sheraz Mian hand-picks one to have essentially the most explosive upside of all.
It’s an American AI firm that’s driving low proper now, however it has rounded up purchasers like BMW, GE, Dell Laptop, and Bosch. It has prospects for not simply doubling however quadrupling within the yr to come back. In fact, all our picks aren’t winners however this one may far surpass earlier Zacks’ Shares Set to Double like Boston Beer Firm which shot up +143.0% in little greater than 9 months and NVIDIA which boomed +175.9% in a single yr.
Free: See Our Top Stock And 4 Runners Up
GoodRx Holdings, Inc. (GDRX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially mirror these of Nasdaq, Inc.
